Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

被引：0

作者：

Sweeney, C. J.

Martin, A. J.

Stockler, M. R.

Begbie, S.

Chi, K. N.

Chowdhury, S.

Coskinas, X.

Frydenberg, M.

Hague, W. E.

Horvath, L. G.

Joshua, A. M.

Lawrence, N. J.

Marx, G. M.

McCaffrey, J.

McDermott, R.

McJannett, M.

North, S. A.

Parnis, F.

Parulekar, W.

Pook, D. W.

Reaume, M. N.

Sandhu, S. K.

Tan, A.

Tan, T. H.

Thomson, A.

Tu, E.

Vera-Badillo, F.

Williams, S. G.

Yip, S.

Zhang, A. Y.

Zielinski, R. R.

Davis, I. D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[4] Concord Repatriat Gen Hosp, Concord Canc Ctr, Concord, Australia

[5] Chris Obrien Lifehouse RPA, Sydney, NSW, Australia

[6] Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[7] Mid North Coast Canc Inst Port Macquarie, Port Macquarie, NSW, Australia

[8] BC Canc Agcy, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] CRUK & Kings Coll London, Guys & St Thomas NHS Fdn Trust Biomed Res Ctr, London, England

[11] Sarah Cannon Res UK, London, England

[12] Monash Univ, Melbourne, Vic, Australia

[13] Australian Urol Associates, Melbourne, Vic, Australia

[14] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[15] Garvan Inst Med Res, Sydney, NSW, Australia

[16] Auckland City Hosp, Auckland, New Zealand

[17] Sydney Adventist Hosp, Wahroonga, Australia

[18] Canc Trials Ireland, Dublin, Ireland

[19] Mater Misericordiae Univ Hosp, Dublin, Ireland

[20] St Vincents Univ Hosp, Dublin, Ireland

[21] Univ Coll Dublin, Dublin, Ireland

[22] ANZUP Canc Trials Grp, Camperdown, NSW, Australia

[23] Cross Canc Inst, Edmonton, AB, Canada

[24] Univ Alberta, Edmonton, AB, Canada

[25] Adelaide Canc Ctr, Adelaide, SA, Australia

[26] Univ Adelaide, Adelaide, SA, Australia

[27] Queens Univ, Canadian Canc Trials Grp CCTG, Kingston, ON, Canada

[28] Monash Hlth, Melbourne, Vic, Australia

[29] Univ Ottawa, Ottawa, ON, Canada

[30] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[31] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[32] Univ Melbourne, Melbourne, Vic, Australia

[33] Waikato Dist Hlth Board, Hamilton, New Zealand

[34] Royal Adelaide Hosp, Adelaide, SA, Australia

[35] Royal Cornwall Hosp, Truro, Cornwall, England

[36] Kingston Hlth Sci Ctr, Kingston, ON, Canada

[37] Macquarie Univ, Sydney, NSW, Australia

[38] Orange Hlth Serv, Cent West Canc Care Ctr, Orange, Australia

[39] Univ Western Sydney, Sydney, NSW, Australia

[40] Eastern Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF UROLOGY | 2021年 / 206卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1519 / 1520

页数：3

共 50 条

[21] OVERALL SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE OR PLACEBO PLUS ANDROGEN DEPRIVATION THERAPY WHO HAD PRIOR LOCAL THERAPY: POST HOC ANALYSIS OF THE PHASE 3 ARCHES TRIAL
Iguchi, Taro
Villers, Arnauld
Shore, Neal D.
Azad, Arun A.
Szmulewitz, Russell Z.
Holzbeierlein, Jeffrey
Alcaraz, Antonio
Alekseev, Boris
Gomez-Veiga, Francisco
Rosbrook, Brad
Lee, Ho-Jin
Haas, Gabriel P.
Armstrong, Andrew J.
Stenzl, Arnulf
JOURNAL OF UROLOGY, 2022, 207 (05): : E455 - E455
[22] Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
Chen, Kenneth
McVey, Aoife
Kasivisvanathan, Veeru
Jenjitranant, Pocharapong
Azad, Arun
Murphy, Declan G.
EUROPEAN UROLOGY, 2022, 82 (01) : 146 - 147
[23] Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
Olivier, Timothee
Tsantoulis, Petros
Prasad, Vinay
EUROPEAN UROLOGY, 2023, 83 (06) : 584 - 585
[24] Re: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Taneja, Samir S.
JOURNAL OF UROLOGY, 2022, 208 (01): : 215 - 216
[25] Current status of androgen deprivation therapy in hormone-sensitive prostate cancer
Alvarez Rodriguez, Sara
Alonso Gordoa, Teresa
Burgos Revilla, Francisco Javier
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (03): : 247 - 257
[26] HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
Sharifi, Nima
Azad, Arun A.
Patel, Mona
Hearn, Jason W. D.
Wozniak, Michele
Zohren, Fabian
Sugg, Jennifer
Haas, Gabriel P.
Stenzl, Arnulf
Armstrong, Andrew J.
CELL REPORTS MEDICINE, 2024, 5 (08)
[27] Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy
Choueiri, Toni K.
Xie, Wanling
D'Amico, Anthony V.
Ross, Robert W.
Hu, Jim C.
Pomerantz, Mark
Taplin, Mary-Ellen
Kantoff, Philip W.
Sartor, Oliver
Oh, William K.
CANCER, 2009, 115 (05) : 981 - 987
[28] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
Tassinari, Davide
Tamburini, Emiliano
Gianni, Lorenzo
Drudi, Fabrizio
Fantini, Manuela
Santelmo, Carlotta
Stocchi, Lucia
Montanari, Francesco
Sartori, Sergio
REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
[29] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Mathieu, Romain
Shariat, Shahrokh F.
EUROPEAN UROLOGY, 2016, 69 (04) : 755 - 756
[30] Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 17 - 18

← 1 2 3 4 5 →